Skip to main content
. 2017 Aug 8;8(48):83872–83889. doi: 10.18632/oncotarget.20040

Figure 5. KX2-391 inhibits expression of TGF-β receptor I and II as well as activation of Smad3 in the injured peritoneum.

Figure 5

Peritoneal membrane was collected at 21 days after CG injury with or without administration of KX2-391(KX2) (5 mg/kg, daily). (A) Peritoneum tissue lysates were subjected to immunoblot analysis with specific antibodies against TGF-β receptor I (TGF-βRI), TGF-β receptor II (TGF-βRII), p-Smad3 and Smad3. Expression levels of TGF-βRI (B), TGF-βRII (C), and Smad3 (E) were quantified by densitometry and normalized with GAPDH, respectively. (D) Expression levels of p-Smad3 were quantified by densitometry and normalized with Smad3. Bars with different letters (a–c) are significantly different from one another (P < 0.05).